Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Single-agent thalidomide for advanced and refractory multiple myeloma].

Yoshiko Okikawa1, Yasuo Takimoto, Masaaki Noda

  • 1Department of Hematology and Oncology, Division of Clinical and Experimental Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|July 30, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stepwise malignant transformation from MHL to UESL via activation of C19MC and loss of TP53.

NPJ precision oncology·2026
Same author

True Hemothorax as the Initial Presentation of Prostate Adenocarcinoma with Pleural Metastasis: A Case Report.

Internal medicine (Tokyo, Japan)·2026
Same author

Effects of external radiation dose on pediatric peripheral blood components after the Great East Japan Earthquake: Fukushima Health Management Survey.

Scientific reports·2026
Same author

Artificial Intelligence-Based Automated Assessment of the Four-Chamber View in Fetal Cardiac Ultrasound Videos.

Bioengineering (Basel, Switzerland)·2026
Same author

Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma.

Oncology letters·2026
Same author

Association between steatotic liver disease and post-traumatic stress symptoms in the Fukushima health management survey.

Scientific reports·2026

Thalidomide shows variable efficacy in refractory myeloma patients, with some benefiting despite side effects like neutropenia. This drug is generally well-tolerated in older adults and may be a key treatment for refractory myeloma.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Refractory myeloma presents a significant therapeutic challenge.
  • Thalidomide has emerged as a potential treatment option for hematologic malignancies.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of thalidomide as a single agent in patients with refractory myeloma.
  • To assess response rates and identify factors influencing treatment outcomes.

Main Methods:

  • Fourteen patients with refractory myeloma received thalidomide (200-400 mg/day).
  • Treatment efficacy was assessed after a minimum of three months.
  • Response criteria by Kakimoto et al. were used for evaluation.

Main Results:

Related Experiment Videos

  • Variable responses were observed, including partial response (PR2, PR3), stable disease, and progressive disease (PD).
  • Six patients discontinued treatment due to intolerable side effects.
  • Neutropenia was a dose-limiting factor, but responsive to G-CSF.
  • Thalidomide was generally well-tolerated in geriatric patients, with manageable side effects.

Conclusions:

  • Thalidomide demonstrates a variable but potential role in managing refractory myeloma.
  • Despite side effects, particularly neutropenia, thalidomide can be considered a well-tolerated option for refractory myeloma, especially in elderly patients.
  • Further research may explore optimizing thalidomide therapy in this patient population.